Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients

Pediatric Transplantation

Volumn 16, Issue 1, 2012, Pages 18-28

  Patel, Manisha ^a,b   Stefanidou, Martha ^a   Long, Caroline B ^a   Fazzari, Melissa J ^a   Tesfa, Lydia ^a   Del Rio, Marcela ^a,b   Lamour, Jacqueline ^a,b   Ricafort, Rosanna ^a,b   Madan, Rebecca P ^a,b   Herold, Betsy C ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

cytomegalovirus; pediatrics; T lymphocytes; transplant

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MONOCLONAL ANTIBODY CD3; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADOLESCENT; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DISEASE COURSE; DYNAMICS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; POSTOPERATIVE PERIOD; RECIPIENT; REVIEW; STEM CELL TRANSPLANTATION; TH1 CELL; TH2 CELL;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; INFANT; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; PEDIATRICS; RENAL INSUFFICIENCY; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION;

EID: 84856012819     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01531.x     Document Type: Review

References (51)

1. Danziger-Isakov LA, Worley S, Michaels MG, et al., The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. Transplantation 2009: 87: 1541-1548.
2. Falagas ME, Paya C, Ruthazer R, et al., Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: A prospective derivation and validation cohort analysis. Transplantation 1998: 66: 1020-1028. (Pubitemid 28513381)
3. Hartmann A, Sagedal S, Hjelmesaeth J,. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006: 82: S15-S17. (Pubitemid 44126861)
4. Von Muller L, Schliep C, Storck M, et al., Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 2006: 78: 394-399. (Pubitemid 43327840)
5. Arend SM, Westendorp RG, Kroon FP, et al., Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996: 22: 920-925. (Pubitemid 26260589)
6. Garcia-Vidal C, Upton A, Kirby KA, Marr KA,. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008: 47: 1041-1050.
7. Manez R, Breinig MK, Linden P, et al., Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl Int 1994: 7 (Suppl 1): S235-S237.
8. Simmonds J, Fenton M, Dewar C, et al., Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 2008: 117: 2657-2661.
9. Toyoda M, Puliyanda DP, Amet N, et al., Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005: 80: 198-205. (Pubitemid 41061676)
10. Madan RP, Campbell AL, Shust GF, et al., A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients. Transplantation 2009: 87: 1318-1324.
11. Manez R, Kusne S, Green M, et al., Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 1995: 59: 1010-1014.
12. Patel R, Paya CV,. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997: 10: 86-124. (Pubitemid 27042833)
13. San Juan R, Aguado JM, Lumbreras C, et al., Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: Data from the RESITRA study group. Am J Transplant 2007: 7: 964-971. (Pubitemid 46481186)
14. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007: 357: 2601-2614. (Pubitemid 350294226)
15. Arthurs SK, Eid AJ, Pedersen RA, et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008: 46: 840-846. (Pubitemid 351417184)
16. Eckle T, Prix L, Jahn G, et al., Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000: 96: 3286-3289.
17. Hodson EM, Craig JC, Strippoli GF, Webster AC,. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008: CD003774.
18. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG,. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005: 143: 870-880. (Pubitemid 46202222)
19. Limaye AP, Bakthavatsalam R, Kim HW, et al., Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004: 78: 1390-1396. (Pubitemid 39507981)
20. Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M,. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int 2002: 15: 615-622. (Pubitemid 36068176)
21. Sia IG, Patel R,. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000: 13: 83-121, table of contents. (Pubitemid 30039345)
22. Wutzler P, Thust R,. Genetic risks of antiviral nucleoside analogues-a survey. Antiviral Res 2001: 49: 55-74. (Pubitemid 32206741)
23. Pescovitz MD, Ettenger RB, Strife CF, et al., Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 2010: 12: 195-203.
24. Vaudry W, Ettenger R, Jara P, et al., Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009: 9: 636-643.
25. Khoury JA, Storch GA, Bohl DL, et al., Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006: 6: 2134-2143. (Pubitemid 44199547)
26. Singh N,. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001: 32: 742-751. (Pubitemid 32221932)
27. Humar A, Paya C, Pescovitz MD, et al., Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004: 4: 644-649. (Pubitemid 38523588)
28. Kumar D, Chernenko S, Moussa G, et al., Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009: 9: 1214-1222.
29. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ,. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007: 195: 633-644.
30. Radha R, Jordan S, Puliyanda D, et al., Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005: 5: 110-117. (Pubitemid 40095134)
31. Sester U, Gartner BC, Wilkens H, et al., Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005: 5: 1483-1489. (Pubitemid 40839442)
32. Micklethwaite KP, Clancy L, Sandher U, et al., Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008: 112: 3974-3981.
33. Schmitt A, Tonn T, Busch DH, et al., Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011: 3: 591-599.
34. Almyroudis NG, Jakubowski A, Jaffe D, et al., Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007: 9: 286-294. (Pubitemid 350059149)
35. Cheng FW, Chan PK, Lee V, et al., Lymphoproliferative response to herpes simplex virus type 1, cytomegalovirus, Epstein-Barr virus, varicella zoster virus, human herpes virus 6, 7, and 8 antigen stimulation in pediatric allogeneic stem cell transplant recipients. Pediatr Transplant 2010: 14: 761-769.
36. Guerin V, Dalle JH, Pedron B, et al., Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplant 2010: 45: 442-449.
37. Koehl U, Dirkwinkel E, Koenig M, et al., Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: Results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr 2008: 220: 348-352.
38. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F,. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006: 108: 1406-1412. (Pubitemid 44232045)
39. Tu W, Chen S, Sharp M, et al., Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol 2004: 172: 3260-3267. (Pubitemid 38263718)
40. Humar A, Michaels M,. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006: 6: 262-274. (Pubitemid 43382161)
41. Maecker HT,. Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 2009: 485: 375-391.
42. Maecker HT, Maino VC,. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 2004: 65: 493-499. (Pubitemid 38686773)
43. Van De Berg PJ, Heutinck KM, Raabe R, et al., Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature. J Infect Dis 2010: 202: 690-699.
44. Gurkan S, Luan Y, Dhillon N, et al., Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010: 10: 2132-2141.
45. Muller TF, Grebe SO, Neumann MC, et al., Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997: 64: 1432-1437. (Pubitemid 27513622)
46. Kogina K, Shoda H, Yamaguchi Y, et al., Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4(+) T cells. Mol Cells 2009: 28: 125-130.
47. Dunn HS, Haney DJ, Ghanekar SA, Stepick-Biek P, Lewis DB, Maecker HT,. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002: 186: 15-22. (Pubitemid 34666909)
48. Tu W, Potena L, Stepick-Biek P, et al., T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006: 114: 1608-1615. (Pubitemid 44547431)
49. Ganepola S, Gentilini C, Hilbers U, et al., Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007: 39: 293-299. (Pubitemid 46322636)
50. Ohnishi M, Sakurai T, Heike Y, et al., Evaluation of cytomegalovirus- specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol 2005: 131: 472-479. (Pubitemid 43899644)
51. Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F,. Mapping T cell epitopes by flow cytometry. Methods 2003: 29: 270-281. (Pubitemid 36513443)